192 related articles for article (PubMed ID: 29878859)
21. Current Inhalers Deliver Very Small Doses to the Lower Tracheobronchial Airways: Assessment of Healthy and Constricted Lungs.
Walenga RL; Longest PW
J Pharm Sci; 2016 Jan; 105(1):147-59. PubMed ID: 26852850
[TBL] [Abstract][Full Text] [Related]
22. A dry powder inhaler with reduced mouth-throat deposition.
Wang ZL; Grgic B; Finlay WH
J Aerosol Med; 2006; 19(2):168-74. PubMed ID: 16796541
[TBL] [Abstract][Full Text] [Related]
23. Oronasal and Tracheostomy Delivery of Soft Mist and Pressurized Metered-Dose Inhalers With Valved Holding Chamber.
Berlinski A; Cooper B
Respir Care; 2016 Jul; 61(7):913-9. PubMed ID: 27006348
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics of Salbutamol Delivered from the Unit Dose Dry Powder Inhaler: Comparison with the Metered Dose Inhaler and Diskus Dry Powder Inhaler.
Moore A; Riddell K; Joshi S; Chan R; Mehta R
J Aerosol Med Pulm Drug Deliv; 2017 Jun; 30(3):164-172. PubMed ID: 28170282
[TBL] [Abstract][Full Text] [Related]
25. De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products.
Leung SS; Tang P; Zhou QT; Tong Z; Leung C; Decharaksa J; Yang R; Chan HK
AAPS J; 2015 Nov; 17(6):1407-16. PubMed ID: 26201967
[TBL] [Abstract][Full Text] [Related]
26. Validating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo Data.
Tian G; Hindle M; Lee S; Longest PW
Pharm Res; 2015 Oct; 32(10):3170-87. PubMed ID: 25944585
[TBL] [Abstract][Full Text] [Related]
27. Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways.
Longest PW; Tian G; Walenga RL; Hindle M
Pharm Res; 2012 Jun; 29(6):1670-88. PubMed ID: 22290350
[TBL] [Abstract][Full Text] [Related]
28. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
[TBL] [Abstract][Full Text] [Related]
29. In Vitro Evaluation of Aerosol Performance and Delivery Efficiency During Mechanical Ventilation Between Soft Mist Inhaler and Pressurized Metered-Dose Inhaler.
Ke WR; Wang WJ; Lin TH; Wu CL; Huang SH; Wu HD; Chen CC
Respir Care; 2020 Jul; 65(7):1001-1010. PubMed ID: 32071134
[TBL] [Abstract][Full Text] [Related]
30. Adapting the Abbreviated Impactor Measurement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clinical data: a scoping study with the "Alberta" idealized throat (AIT) inlet.
Mitchell J; Copley M; Sizer Y; Russell T; Solomon D
J Aerosol Med Pulm Drug Deliv; 2012 Aug; 25(4):188-97. PubMed ID: 22857270
[TBL] [Abstract][Full Text] [Related]
31. Understanding the effects of inhaler resistance on particle deposition behaviour - A computational modelling study.
Cai X; Dong J; Milton-McGurk L; Lee A; Shen Z; Chan HK; Kourmatzis A; Cheng S
Comput Biol Med; 2023 Dec; 167():107673. PubMed ID: 37956626
[TBL] [Abstract][Full Text] [Related]
32. [Respimat®, first Soft Mist™ inhaler: new perspectives in the management of COPD].
Henriet AC; Marchand-Adam S; Mankikian J; Diot P
Rev Mal Respir; 2010 Dec; 27(10):1141-9. PubMed ID: 21163393
[TBL] [Abstract][Full Text] [Related]
33. Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships.
Lim JG; Shah B; Rohatagi S; Bell A
Am J Ther; 2006; 13(1):32-42. PubMed ID: 16428920
[TBL] [Abstract][Full Text] [Related]
34. In Vitro-In Vivo Correlations Observed With Indacaterol-Based Formulations Delivered with the Breezhaler®.
Weers JG; Clark AR; Rao N; Ung K; Haynes A; Khindri SK; Perry SA; Machineni S; Colthorpe P
J Aerosol Med Pulm Drug Deliv; 2015 Aug; 28(4):268-80. PubMed ID: 25517988
[TBL] [Abstract][Full Text] [Related]
35. Use of Airway Replicas in Lung Delivery Applications.
Golshahi L; Finlay WH; Wachtel H
J Aerosol Med Pulm Drug Deliv; 2022 Apr; 35(2):61-72. PubMed ID: 35262408
[TBL] [Abstract][Full Text] [Related]
36. Lung Deposition and Inspiratory Flow Rate in Patients with Chronic Obstructive Pulmonary Disease Using Different Inhalation Devices: A Systematic Literature Review and Expert Opinion.
Baloira A; Abad A; Fuster A; García Rivero JL; García-Sidro P; Márquez-Martín E; Palop M; Soler N; Velasco JL; González-Torralba F
Int J Chron Obstruct Pulmon Dis; 2021; 16():1021-1033. PubMed ID: 33907390
[TBL] [Abstract][Full Text] [Related]
37. In-vitro characterisation of metered dose inhaler versus dry powder inhaler glucocorticoid products: influence of inspiratory flow rates.
Feddah MR; Brown KF; Gipps EM; Davies NM
J Pharm Pharm Sci; 2000; 3(3):318-24. PubMed ID: 11177650
[TBL] [Abstract][Full Text] [Related]
38. Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler.
Hodder R; Price D
Int J Chron Obstruct Pulmon Dis; 2009; 4():381-90. PubMed ID: 19888356
[TBL] [Abstract][Full Text] [Related]
39. A review of the development of Respimat Soft Mist Inhaler.
Dalby R; Spallek M; Voshaar T
Int J Pharm; 2004 Sep; 283(1-2):1-9. PubMed ID: 15363496
[TBL] [Abstract][Full Text] [Related]
40. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.
Kässner F; Hodder R; Bateman ED
Drugs; 2004; 64(15):1671-82. PubMed ID: 15257628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
